Hep C Drug Trends: Cost Driver In 2014, But “Leveling Off” Coming, CMS Actuaries Say
This article was originally published in RPM Report
CMS actuaries attribute an increase in health spending in 2014 to the expansion of Medicaid and private health insurance coverage and rapid growth in retail drug spending, particularly for new hep C drugs.
You may also be interested in...
Retail drug spending rose just 1.3% in 2016, following growth rates of 8.9% and 12.4% in 2015 and 2014, respectively. Moderating trend is reported just ahead of two congressional hearings on drug pricing.
CMS streamlined process for enhanced payments is having an impact: seven antibiotic applications for New Technology Add-On Payment status in 2021—including one for a product that has been marketed for more than five years.
Updated guidance on its authority to mandate postmarketing studies affirms that a new power to impose requirements to look for diminished efficacy reaches beyond the opioid drug class.